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Hidradenitis suppurativa is a chronic skin condition, 
charac terized clinically by painful, recurrent, deep- 
seated nodules and suppuration, and histologically by 
hyper trophic scarring of apocrine gland bearing skin 
and sinus tracts. The overall consequence of the disease 
is considerable tissue remodelling and the underlying 
alterations in innate immunity are poorly understood. 
The aim of this study was to evaluate the expression of 
human beta-defensin 2, tumour necrosis factor (TNF)-α 
and matrix metalloproteinase-2 in skin lesions of pa-
tients with hidradenitis suppurativa. A total of 14 skin 
samples from patients and 2 skin samples from healthy 
volunteers were evaluated by immunohistochemistry. 
Human beta-defensin 2 was negative in 12/14 specimens. 
Elevated expression of metalloproteinase-2 was observed 
in keratinocytes, fibroblasts and inflammatory cells in 
dermis, sweat glands, hair follicles and sinus tracts, sug-
gesting a key role for hidradenitis suppurativa pathoge-
nesis. Decreased human beta-defensin 2 in the presence 
of inflammatory (TNF-α-containing) cells suggests a 
decreased innate immunity in hidradenitis suppurativa-
affected skin. Key words: hidradenitis suppurativa; anti-
microbial peptides; cytokines; innate immunity; matrix 
metalloproteinase-2.
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Hidradenitis suppurativa (HS) is a chronic skin condition 
characterized by painful, deep-seated, recurrent nodules 
commonly ending in abscesses, and sinus tracts with 
suppuration and hypertrophic scarring of apocrine gland 
bearing skin (1). The histological picture varies with the 
severity of the disease. Perifollicular lymphocytic inflam-
mation and small or absent sebaceous glands appear to 
be early changes, whereas poral occlusion, inflamma-
tion of hair follicle, apocrine and eccrine sweat glands, 
diffuse inflammation in dermis, abscesses and scarring 
occur later (2, 3). Clinically and histologically tissue 
remodelling occurs. A hallmark histological feature of 
HS is the sinus tract; an elongated cavity extending into 
the dermis or even subcutis with squamous epithelium 
lining the walls (4). It is thought that sinus tracts represent 
expansive growth due to tissue remodelling/healing of 
the lesions based on the finding of immature keratins and 
stem-cell-like cells (5, 6).
HS has a complex pathogenesis that involves folli-
cular inflammation. Genetic, endocrinological, bacte-
rial, environmental and pharmacological factors, as well 
as smoking and obesity, have been described as possible 
pathogenic factors (7, 8). The observation that tumour 
necrosis factor (TNF)-α inhibitors may be used in the 
treatment of HS has led recently to increased interest 
in the role of the immune system and inflammation in 
HS (9–12). Disturbances of the innate immune system 
have been described (13–16).
The aim of this study was therefore to evaluate the 
expression of human beta-defensin 2 (HBD2), TNF-α 
and matrix metalloproteinase-2 (MMP-2) in skin lesions 
of patients with HS.
MATERIALS AND METHODS
The patient group comprised 11 female and 3 male patients 
with HS, age range 22–59 years. All patients were Caucasian. 
Half of the patients had axillar and half had inguinal lesions. 
All specimens contained sinus tracts, as seen in preparations 
stained with haematoxylin and eosin. As a negative control we 
used healthy skin tissue from a similar region obtained from 2 
volunteers, after obtaining written informed consent. The study 
was performed according to the principles of the Declaration 
of Helsinki and was approved by the local ethics committee. 
Sections 4 µm thick were prepared from the paraffin-em-
bedded tissue. Human beta-defensin 2 (cat no. AF 2758, LOT 
VJU015051, obtained from goat, 1:100 dilution, R&D Sys-
tems, Germany), TNF-α (code ab 6671, obtained from rabbit, 
1:100 dilution, Abcam, Cambridge, UK) and MMP-2 (cat no. 
AF902, LOT DUB034081, obtained from goat, 1:100 dilution, 
R&D Systems) were used in biotin–streptavidin immunohisto-
chemistry (17) and 3 slides per biopsy were examined.
The intensity of immunostaining was graded semiquantita-
tively. Samples with few positive structures in the visual field 
were labelled +, samples with a moderate number of positive 
structures in the visual field were labelled ++, samples with 
numerous positive structures in the visual field were labelled 
+++, and those with an abundance of positive structures in the 
visual field were labelled ++++ (18).
Non-parametric statistics were used and Spearman’s rank 
correlation coefficient was calculated to compare co-expression 
of the markers in the biopsies.
Findings were photographed with a Leica DC 300F camera and 
analysed with image-processing and analysis software Image Pro 
Plus 6.0 (Media Cybernetics, Silver Spring, Maryland, USA).
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RESULTS
Sinus tracts and cysts, large intradermal inflammatory 
infiltrates containing an abundance of plasma cells, 
lymphocytes and epithelioid cells were observed. Arte-
riole sclerosis and destruction of hair follicle structures 
was also observed. Major secondary changes due to 
inflammation were seen in the morphology of apocrine 
sweat glands, where prominent, almost total, vacuo-
lization in the glandular cells was observed. At the 
same time, we found groups of apocrine sweat glands 
presenting also atrophy and proliferation (Fig. 1). 
HBD2 stained negative in 12/14 samples, where 
some weakly stained cells were detected. MMP-2 and 
TNF-α positive structures were found in all skin samp-
les. MMP-2 was seen in keratinocytes, fibroblasts and 
inflammatory cells (macrophages and lymphocytes) 
in dermis, sweat glands, outer epithelial sheath of hair 
follicle and sinus tracts (Fig. 2). A moderate number 
of TNF-α-positive inflammatory cells was seen in the 
dermis, but the level varied from only a few cells to an 
abundance of strongly positive cells, correlated with the 
level of inflammation in the tissue. Cytokine-positive 
macrophages were seen both around the sweat glands 
and hair follicles (Fig. 3). 
In comparison with skin from patients with HS, in 
healthy skin from controls, TNF-α-positive cells were 
not present, while a moderate number of HBD2- and 
MMP-2-positive structures were found in the epithe-
lium, subepithelium and sweat glands. All semiquanti-
tative results are summarized in Table I.
DISCUSSION
This study suggests that mature HS lesions do not con-
tain HBD2, while both TNF-α and MMP-2 are found.
HBD2 has not been extensively studied in HS, al-
though it is one of the most common antimicrobial 
peptides of the skin (19). Only 2/14 lesions stained po-
sitively for HBD2, suggesting that it is either consumed 
or not expressed. Antimicrobial peptides are a very large 
and diverse part of the innate immune system. A recent 
study examined the levels of HBD3 in lesional skin, 
and found unchanged levels in very severe HS, while 
expression of the antimicrobial peptide ribonuclease 
7 was diminished and dermcidin levels were unchan-
ged compared with healthy skin (20). Another recent 
study evaluated HBD2 and HBD4 in lesional and non-
lesional untreated HS skin and, in agreement with our 
observations, found significantly decreased expression 
compared with healthy skin (15). 
HBD2 appears to be the first human defensin produ-
ced when epithelial cells are stimulated by, for example, 
microorganisms such as Pseudomonas aeruginosa, or 
cytokines such as TNF-α and interleukin (IL)-1 beta. 
The lack of HBD2 expression is therefore noteworthy 
in the presence of the TNF-α-rich infiltrate found in HS. 
The mechanism behind the lack of HBD2 is not clear. 
TNF-α induces further expression of HBD2, and was 
expressed prominently in our skin sample. However, 
the skin microflora was not evaluated at the same time, 
and could have been of importance in the induction of 
HBD2. As defensin plays an important role in protection 
against Gram-negative bacteria, we therefore cannot 
exclude Gram-negative bacteria as a potential causative 
factor of HS. 
TNF-α in HS has been studied previously, partly due 
to the observation that TNF-α inhibitors may be used 
to treat the condition. We found a wide distribution of 
TNF-α-positive cells in the tissue, providing broad con-
tact with epithelia, where HBD2 expression could have 
Fig. 1. Groups of apocrine sweat glands showing concomitant proliferation 
and atrophy. Broad arrow pointing at the proliferating glands, thin one at 
the atrophic ones. Matrix metalloproteinase-2 immunohistochemistry, × 200.
Fig. 2. Metalloproteinase-2 (MMP-2)-positive terminal follicle at infra-
infundibular region and surrounding large plasma cells-dominating 
inflammatory infiltrate. Numerous epitheliocytes, macrophages and fibroblasts 
expressing matrix metalloproteinase. Broad arrow at the inflammatory cells 
and thin at the epidermis. MMP-2 immunohistochemistry, × 100.
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been induced. A previous study detecting serum TNF-α 
levels has also shown significantly higher levels in HS 
patients compared with healthy controls (11). This was 
supported by a study suggesting that isolated monocytes 
from the peripheral blood of HS patients were unable 
to produce more TNF-α on stimulation, suggesting that 
they were completely stimulated in vitro (21). TNF-α 
has also been found previously to be significantly 
elevated in HS lesional and perilesional skin, together 
with interleukin-1-β and interleukin-10 (9). Our study 
focused on TNF-α expression in inflammatory cells in 
HS-affected tissue. The results support the theory of a 
notable presence of TNF-α, and thus probably support 
the rationale for therapy with anti-inflammatory block-
ers in patients with HS. 
Finally, we detected vigorous expression of MMP-2 
in HS-affected skin. While it is important to mention 
that MMP matrilysin has been found to participate in 
the normal function of dermal exocrine glands (22), 
we speculate that MMP-2, which is a tissue degrada-
tion enzyme, is a common key event for HS due to the 
expansive growth of the lesions, which links to the 
theory that HS is due to dysregulated repair of unspecific 
tissue damage. In addition, the excessive expression of 
MMP-2, providing a boundless proteolytic environment, 
may be the inactivator of HBD2 and accordingly limit 
antimicrobial defence in patients with HS. Interestingly, 
MMP-2 has been detected previously in skin in signi-
ficantly higher levels in neutrophilic dermatoses, and 
various studies report a role of MMP-2 in cancer (23–
29). It may therefore be speculated that the increased 
MMP-2 expression is related to the histological picture 
of HS, with its proliferating epithelial strands and sinus 
tract formation (30). Elevated expression of MMP-2 
observed in keratinocytes, fibroblasts and inflammatory 
cells in dermis, sweat glands, outer epithelial sheath of 
hair follicle and sinus tracts suggests its key role in HS 
pathogenesis.
A decrease in the antimicrobial protein HBD2 on 
the background of presence of inflammatory cytokines 
(TNF-α-containing cells) indicates a decreased innate 
immunity in HS-affected skin. 
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